me-SAL-a-meen 
Delzicol, Lialda, and Pentasa:
Apriso:
Asacol HD:
Canasa:
Rowasa:
Absorption: 28% absorbed following oral administration; 10–30% absorbed from the colon, depending on retention time, following rectal administration.
Distribution: Unknown.
Metabolism/Excretion: Some metabolism occurs, site unknown; mostly eliminated unchanged in the feces.
Half-life: Oral — 12 hr (range 2–15 hr); Rectal — 0.5–1.5 hr.
Contraindicated in:
Use Cautiously in:
CV: pericarditis.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMATIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), hair loss, photosensitivity, rash.
EENT: pharyngitis, rhinitis.
GI: HEPATOTOXICITY, diarrhea, eructation (PO), flatulence, nausea, pancreatitis, vomiting.
GU: interstitial nephritis, nephrolithiasis, renal failure.
Local: anal irritation (enema, suppository).
MS: back pain, myalgia.
Neuro: headache, dizziness, malaise, weakness.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), acute intolerance syndrome, fever.
Drug-Drug:
Treatment of Ulcerative Colitis
12 yr and 54–90 kg): Delzicol — 27–44 mg/kg/day in 2 divided doses (max dose = 2.4 g/day) for 6 wk.12 yr and 33–53 kg): Delzicol — 37–61 mg/kg/day in 2 divided doses (max dose = 2 g/day) for 6 wk.12 yr and 17–32 kg): Delzicol — 36–71 mg/kg/day in 2 divided doses (max dose = 1.2 g/day) for 6 wk.Maintenance of Remission of Ulcerative Colitis
Treatment of Ulcerative Proctosigmoiditis
Treatment of Ulcerative Proctitis
Apriso, Asacol, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, Rowasa
(Generic available)
(clinical improvement)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | unknown | unknown | 6–8 hr |
| ER | 2 hr | 9–12 hr | 24 hr |
| Rectal | 3–21 days | unknown | 24 hr |
NDC Code*